Reduction in nocturnal urinary frequency and improvement of fatty liver in SGLT-2 inhibitors.

Reduction in nocturnal urinary frequency and improvement of fatty liver in SGLT-2 inhibitors: a randomized controlled trial - Reduction in nocturnal urinary frequency and improvement of fatty liver in SGLT-2 inhibitors: a randomized controlled trial

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000054278

Enrollment

135

Registered

2024-04-29

Start date

2024-04-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Prescription of 20 mg of tofogliflozin in men and women with type 2 diabetes Prescription of 5 mg of dapagliflozin in men and women with type 2 diabetes Prescription of 10 mg of empagliflozin in men

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults of 30 years and over with HbA1c >= 8.0% of type 2 diabetes and metabolic dysfunction associated steatohepatitis (MASH)

Exclusion criteria

Exclusion criteria: Insulin users Type 1 diabetes Mental illness Liver cirrhosis Renal failure

Design outcomes

Primary

Measure	Time frame
Change in the frequency of nocturnal urine (23:00-6:00)	—

Secondary

Measure	Time frame
Improvement of fatty liver	—

Countries

Japan

Contacts

Public ContactTetsuya Kawahara

Shin Komonji Hospital Endocrinology and Diabetes

k-tetsuy@med.uoeh-u.ac.jp0933911001

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026